

## **MEDIA STATEMENT**

PHILOGEN SPA ANNOUNCES PARTICIPATION IN “7TH ANNUAL WORLD ADC BERLIN MEETING”, FEBRUARY 20-22, 2017, BERLIN, GERMANY

[Philogen S.p.A.](#) and its fully owned subsidiary [Philochem AG](#), announce their participation to the “[7<sup>th</sup> annual World ADC Berlin meeting](#)” that will take place at the Maritim proArte Hotel Berlin, on February 20-22, 2017.

World ADC Berlin meeting will gather more than 300 of the leading Antibody Drug Conjugated minds to share data, insights and experiences, on how to develop the next generation of clinically impactful ADCs.

**Dr. Martin Mattarella**, head of chemistry at Philochem, will give a talk with the title “[Design & Development of a Non-Internalizing ADC Product](#)”. The presentation is scheduled for Wednesday, 22<sup>nd</sup> February.

For additional news and press release topics, visit: <http://www.philogen.com/en/news/>

### **About the Philogen group**

Philogen is a clinical-stage biotechnology company engaged in the discovery and development of novel biopharmaceutical products. Philogen’s strategy is to deliver bioactive agents, for example cytokines or drugs to the site of disease using antibodies and ligands that specifically and efficiently target stromal antigens. This technology has generated a strong proprietary pipeline of clinical-stage products and also pre-clinical compounds in an array of disease indications. Philogen is headquartered in Siena, Italy, and has research activities at its subsidiary company Philochem in Zürich, Switzerland. Philogen is independently owned, and has signed agreements with several major pharmaceutical companies. For more information, please visit [www.philogen.com](http://www.philogen.com)

---